Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has informed BSE that its Board of Directors will meet on Wednesday, November 12, 2025, at 2:00 PM to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025. This is a routine regulatory intimation filed under SEBI LODR Regulation 29 ahead of the upcoming results announcement. The company's trading window remains closed for designated persons until November 14, 2025, i.e., 48 hours after the results are approved, which is standard insider trading compliance practice.
This is a procedural filing with no direct impact on shareholders or stock price. Investors should watch for the actual Q2/H1 FY26 results to be released on or after November 12, 2025, which will provide insight into the company's financial performance and could influence near-term stock sentiment.